Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724566 | 1.00 | MC4R (0.39) | MC4RHRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14035294 | 0.84 | SLC6A4 (0.52) | MC4RSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4099473 | 0.84 | SLC6A4 (0.43) | MC4RHRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4103236 | 0.84 | SLC6A4 (0.43) | MC4RHRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL4093033 | 0.76 | SCN5A (0.40) | HRH3OPRD1OPRM1 | |
| SCHEMBL4095513 | 0.76 | SCN5A (0.40) | HRH3OPRD1OPRM1 | |
| SCHEMBL13750181 | 0.76 | HRH3 (0.47) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4099505 | 0.76 | OPRL1 (0.47) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL13749435 | 0.76 | HRH3 (0.47) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4099664 | 0.76 | OPRL1 (0.47) | HRH3SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | MC4R 4200/4885HRH3 2328/4885SLC6A4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.